This document provides information on the 3rd Annual Conference on 3D Cell Culture taking place on February 20-21, 2019 in London, UK. The conference will feature presentations and panel discussions on developing 3D cell culture technologies and their applications in drug development and disease modeling. Speakers will discuss topics such as organ-on-chip technologies, 3D bioprinting, developing translationally relevant 3D models, and using organoids and 3D neuronal/retinal models for toxicity testing. A pre-conference workshop on February 19th will demonstrate a new technique for histological assessment of 3D spheroid arrays.

1. www.3D-cellculture.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
3D you can see – planar 3D spheroid arrays for histology
Workshop Leaders:
Dr. Patrick Kugelmeier, Founder, Director of Science, Kugelmeiers
Dr. Michael Raghunath, Professor for Biochemistry, Protein Technology and Tissue Engineering, Zurich University of Applied Sciences
8.30 - 12.30
PLUS AN INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOP | TUESDAY 19TH FEBRUARY 2019, COPTHORNE TARA HOTEL, LONDON, UK
CHAIRS FOR 2019:
Nicola Valeri, Gastrointestinal Cancer Biology and
Genomics Team Leader, The Institute of Cancer
Research
Stefan Przyborski, Professor of Cell Technology,
University of Durham
GUEST SPEAKER:
• Bill Mattes, Director, Division of Systems Biology, FDA
SPEAKERS INCLUDE:
• Asli Akidil, Cell and Molecular Scientist, AstraZeneca
• Gary Allenby, Business Development Director and Chief
Scientific Officer, Aurelia Biosciences
• Jason Ekert, Head of Complex In Vitro Models, GSK
• Philip Hewitt, UK and Eurotox Registered Toxicologist,
Head of Early Investigative Technology, Merck
• Stefan Kustermann, Lab Head, Investigative Safety, Roche
• Veronique Barban, Expert Virology, Research and
Nonclinical Safety Department, Sanofi Pasteur
HIGHLIGHTS IN 2019:
• Discuss organ-on-chip technologies and their
applications in the pharmaceutical industry
• Engage in a panel discussion on whether 3D cell
culture will replace animal models
• Gain insight into the global developments in 3D cell
culture and the impact on researchers
• Discover the development of 3D eye models for
early assessment of retinal toxicity
• Explore the use of musculoskeletal regeneration in
harnessing preclinical models for tissue repair
WORKSHOP: 19TH
CONFERENCE: 20TH - 21ST
FEB
2019COPTHORNE TARA HOTEL, LONDON, UK
Delivering updates on the development and
application of human organs and tissues in vitro
SMi presents their 3rd Annual Conference on…
3D Cell Culture
BOOK BY 31ST OCTOBER AND SAVE £400
BOOK BY 30TH NOVEMBER AND SAVE £200
BOOK BY 14TH DECEMBER AND SAVE £100
SMi Pharma
@SMiPharm
#SMi3DCellCulture
Sponsored by

2. 3D Cell Culture
Day One | Wednesday 20th February 2019 www.3D-cellculture.com
8.30 Registration & Coffee
9.00 Chair’s Opening Remarks
Stefan Przyborski, Professor of Cell Technology,
University of Durham
DEVELOPMENT AND APPLICATION OF
HUMAN ORGANS AND TISSUES IN VITRO
OPENING ADDRESS
9.10 Development and application of bioengineered models
of human tissues in vitro
• Novel cell culture technologies are providing new
opportunities to bioengineer human tissue constructs in vitro
• Such tissue equivalent models enable the development of new
in vitro assays and assessment of drug activity
• Building models that more accurately simulate normal tissue
structure for R&D use will enhance the predictive accuracy of in
vitro assays
• Here we demonstrate the potential of such technology
to create new opportunities for discovery research, drug
assessment and safety screening
Stefan Przyborski, Professor of Cell Technology,
University of Durham
SPOTLIGHT SESSION
9.45 Tools, not toys: from innovation to regulatory application
• An incredibly important consideration for any new
technology is what decisions will be made by its use
• The “Context of Use” should guide what information is needed
to “validate” a new technology
• The role of new technologies in regulatory processes can be
informed by Biomarker / Drug Development Tool Qualification
process developed by FDA and EMA
William Mattes, Director, Division of Systems Biology,
U.S. Food and Drug Administration
10.20 Morning Coffee
10.50 Improving preclinical predictivity with human-based 3D models
• The failure of compounds during clinical development has been
linked to the poor predictivity of models used for basic research
and drug development
• New technologies are rapidly evolving which enable complex
3D cell culture models to be built with human cells or tissue, and
which closely mimic some aspects of human physiology and
disease
• Application of these technologies to basic research and drug
development holds the promise of being able to better predict
safe or efficacious medicines before clinical trials are initiated
• In addition, these new ways of working often bring time or
money savings, and minimise the reliance on animal models
• In this talk the principles of implementing the 3Rs with new
technology will be illustrated with examples from the NC3Rs and
wider research community
Samuel Jackson, Programme Manager, Disease Models, NC3Rs
11.25 3D cell culture in the advancement of medicines discovery
• The need for 3D models in developing new medicines and
current challenges
• Developments in 3D models that are advancing medicines
discovery
• How the Medicines Discovery Catapult is using 3D cell cultures
in collaborative projects
• Examples/case studies from our work
Sally Price, Head of Cell and Translational Science,
Medicines Discovery Catapult
12.00 Musculoskeletal regeneration harnessing preclinical models for
tissue repair
• Overview of UKRMP Smart Materials HUB work in the field
• Development of ex vivo and organotypic models for skeletal
tissue repair – a simple screen approach
• Use of innovative biomaterials in skeletal repair
• Translation and challenges of skeletal tissue engineering
approaches for patient benefit
Richard Oreffo, Director, Centre for Human Development,
University Of Southampton
12.35 Networking Lunch
PANEL DISCUSSION:
13.35 Will 3D Cell Culture replace animal models?
• Advantages and disadvantages of 3D Cell Culture vs
animal models
• Where are we now; and where do we need to go?
• Is the technology advanced enough to fully replace animal
models?
• Future of 3D Cell Culture
Stefan Przyborski, Professor of Cell Technology,
University of Durham
Helena Hogberg, Deputy Director, Center for Alternatives to
Animal Testing, Johns Hopkins University Bloomberg School of
Public Health
Jason Ekert, Head of Complex In Vitro Models, GSK
14.10 The future of 3D cell culture in medicine: blending medical
devices and cells to build organs
• Organ and tissue design and development
• State of the art for 3D Bioprinting
• Limitations of current systems and methods
• Pathways to full organ replacement
Melanie Matheu, Founder, CEO , Prellis Biologics
BIOPRINTING AND IMAGING TECHNOLOGIES
14.45 Amplification of extracellular matrix via macromolecular crowding
in 2D, 3D, cell culture and in bioprinting
• The importance of the cellular microenvironment in controlling
cell behavior and fate
• Current highly aqueous culture conditions impair efficient ECM
deposition
• Overcoming this issue by introducing macromolecular crowding
(MMC) into the culture medium of monolayer cultures or
hydrogels
• MMC adopted by the pharma industry for antifibrotic screening:
production of stem cell matrix, and tuning the microarchitecture
of bioprinted collagen hydrogels
Michael Raghunath, Head Center for Cell Biology & Tissue
Engineering Director Competence Center TEDD,
Zurich University of Applied Sciences
15.20 Afternoon Tea
15.50 Meeting tissue engineering challenges with 4D bioprinting
• Laser assisted bioprinting
• 3D bioprinting
• Tissue engineering
• 3D in vitro tissue models
Kevin Fournier, Sales and Applications Manager, Poietis
16.25 3-dimensional imaging of organoids
• Protocol of 3D imaging of intact organoids
• High throughput 3D live imaging and automated quantification
• In vivo model for human cancer based on organoid technology
Anne Rios, Principal Investigator, Princess Maxima Center
SPOTLIGHT SESSION
17.00 Automated confocal imaging and analysis process for
liver-on-a-chip platform
• Advantages of a liver-on-a-chip platform over traditional 2D
models
• Introduction to automated confocal imaging and analysis
process on liver-on-a-chip platform
• Benefits of using automated imaging and analysis process as a
detection method
• Challenges of optimizing the automated analysis process for the
quadruple co-culture liver-on-a-chip platform
Asli Akidil, Cell and Molecular Scientist, AstraZeneca
17.35 Chair’s Closing Remarks and Close of Day One
Register online at www.3D-cellculture.com
SPONSORED BY:
TEDD Competence Centre (Tissue Engineering for Drug Development and Substance Testing)
TEDD is a collaborative innovation platform, dedicated to 3D cell culture technology and organ-like tissue models for drug
development, substance testing, personalized and regenerative medicine. TEDD community is composed of partners
from academia, clinical medicine and industry and comprises a spectrum from young spin-off company to world player.
www.zhaw.ch/icbt/tedd
InoCure s.r.o. is a SME focused on development of advanced nanomaterials for life science use. We are developing drug delivery
and scaffolding systems based on nano/microparticles (μSphere technology) and nanofibrous systems (InoMATRIX technology).
InoCure helps its partners design next generation of drug delivery systems and introduce those into mass production.
www.inocure.cz

3. 3D Cell Culture
www.3D-cellculture.com Day Two | Thursday 21st February 2019
8.30 Registration & Coffee
9.00 Chair’s Opening Remarks
Nicola Valeri, Team Leader, The Institute of Cancer Research
RECENT DEVELOPMENTS IN 3D CELL CULTURE
OPENING ADDRESS
9.10 3D goes clinical — Modified islet transplantation as
blueprint for future 3D cell transplantation
• The future operating theatre will be the laboratory
• 3D cell culture as a prerequisite for future cell transplantation
applications
• Challenges in preparing a clinical trial for cell therapy using the
example of modified islet transplantation
• Consequences for future cell therapies
Patrick Kugelmeier, Director of Science, Kugelmeiers
9.45 Not all 3-D is the same! The development of cell-based assay formats
for compound profiling using electrospun fibre in novel ways
• Electrospun fibres have been used to generate a high
throughput chemotaxis model for profiling compounds using
human derived primary cells in 3-D
• Electrospun fibres can be used to grow human iPSC derived
cortical neurones for profiling of compounds for safety
assessement in 3-D
• Who needs a plate washer – we will show data generated in a
number of kinetic cell based binding assays in which we have
used electrospun fibre to manipulate cells to improve assay
performance
• Combination of electrospun fibres and 3-D printing – an
example of how to generate more complex models of biology
in a well plate
Gary Allenby, Business Development Director and Chief Scientific
Officer, Aurelia Bioscience
10.20 Morning Coffee
SPOTLIGHT SESSION
10.50 Developing translationally relevant 3D models for
pre-clinical drug development
• Challenges and opportunities in developing translationally
relevant 3D models
• What components need to be considered when developing
human relevant and predictive 3D models?
• How do we characterize, scale and automate 3D models in
preclinical drug discovery?
Jason Ekert, Head of Complex In Vitro Models, GSK
CASE STUDIES: 3D MODELS AND THEIR APPLICATIONS
11.25 Human 3D neuronal models for drug safety assessment
• Presentation of 3D neuronal model of the brain and eye/retina
for drug safety testing
• Application of such models for drug safety testing, current gaps
and future opportunities
• What’s next? Future trends and needs in the field
Stefan Kustermann, Lab Head, Roche
12.00 A microfluidic platform for 3D oncology
• Performing drug screening of tissue derived from cancer patient
biopsies using physiologically relevant 3D tumour models
presents challenges due to the limited amount of available cell
material
• We have developed a microfluidic platform that enables
drug screening of multicellular spheroids derived from tumour
biopsies, allowing extensive anticancer compound screening
prior to treatment
• This technology could prove a useful tool for personalised
medicine and future drug development
Michele Zagnoni, Senior Lecturer, University Of Strathclyde
12.35 Networking Lunch
13.35 Human induced pluripotent stem cells generate light responsive
retinal organoids with variable and nutrient dependent efficiency
• Pluripotent stem cell differentiation to 3D retinal organoids
• Application of 3D retinal organoids for toxicology studies
• Disease modelling with pluripotent stem cells
• 3D retinal organoids provide a useful source of cells for
photoreceptor transplantation
Majilida Lako, Professor of Stem Cell Science, Newcastle University
14.10 CRACK-IT: Development of 3D eye models for early assessment of
retinal toxicity
• What is a CRACK-IT challenge?
• Why Establish human 3D retinal cell model: perspective from the
pharmaceutical industry
• iPSC derived multiplayer retinal models: first functional
characterization – and safety testing
• Potential use of 3D retinal models in future toxicity testing
paradigms
Philip Hewitt, Head of Early Investigative Toxicology, Merck KGaA
SPOTLIGHT SESSION
14.45 3D models for infectious diseases and vaccines
• Potential and Limits of 3D-models for industrial development
of human vaccines
• Case study: 2D and 3D liver models for yellow fever virus
viscerotropism assessment
Veronique Barban, Expert Virology, Research and Nonclinical
Safety Department, Sanofi Pasteur
15.20 Afternoon Tea
15.50 Organoids: a patient in the lab
• Patient derived adult stem cells Organoids are a clinically
relevant in vitro model
• Genetically stable, long term expanding, epithelial cultures
• Capture patient population heterogeneity and intra patient
heterogeneity
• Use of human airway organoids for the in vitro study of
hereditary, malignant or infectious pulmonary diseases
Robert Vries, Managing Director, Hubrecht Institute
16.25 3D human induced pluripotent stem cell models of the central
nervous system
• Characterization and overview of the 3D models
• Functional endpoints for models of the central nervous system
• Application of our 3D models for toxicology
• Application of our 3D models for disease
Helena Hogberg, Deputy Director, Center for Alternatives to
Animal Testing, Johns Hopkins University Bloomberg School of
Public Health
SPOTLIGHT SESSION
17.00 Patient-derived organoids: Promises, hurdles and potential
clinical applications
• Bio-banking organoids from metastatic patients enrolled in
clinical trials
• Characterizing organoids and parental biopsies
• Performing High-throughput screenings in 3-D
• Co-clinical trial results: comparing responses observed in the lab
with patients’ outcomes
Nicola Valeri, Team Leader, The Institute of Cancer Research
17.35 Chair’s Closing Remarks and Close of Day Two
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
SUPPORTED BY:
Want to know how you can get involved? Interested in promoting your services to this market?
Contact Simi Sapal, SMi Marketing Manager on +44 (0) 20 7827 6162 or
email: ssapal@smi-online.co.uk
OFFICIAL MEDIA PARTNERS:

4. HALF-DAY PRE-CONFERENCE WORKSHOP
Tuesday 19th February 2019
Copthorne Tara Hotel, London, UK
8.30-12.30
3D you can see –
planar 3D spheroid arrays for histology
Workshop overview:
Certain standard procedures are indispensable for life
sciences. Histology is one of them. But for 3D spheroids,
histological assessment so far has been done as irregular
bulk without a clear optical plane. Thanks to the totally
regular array spheroid building in the Sphericalplate 5D, we
will show how to catch spheroids with polymerizing gel and
processing histology to a planar array of 750 spheroids. This
perfectly fits a microscope slide and allows the user to do
histological assessment of 3D spheroids like never before.
Why you should attend this workshop:
• If you do histology on 3D spheroids, this workshop is for you.
It offers you a new dimension of scalability and analysis flow
• Various research areas like cancer screening and stem cell
research need an individual understanding of spheroid
biology – cut in one plane x 750 samples gives you
unparalleled data accuracy
• Statistical power will be much higher, as you can rely on
more, regular data points
• Various showcases like hypoxia effects on spheroid biology
or cell population heterogeneity can be studied more
accurately when spheroids are organised in one plane
Agenda
8.30 Registration & Coffee
9.00 Opening Remarks and Introductions
9.10 The spheroidal world of cell culture
• Why 3D, why spheroids
• Current methods to make spheroids; pro’s and
cons
9.50 Applications and impact
• Spheroid Transplantation – the workhorse of
regenerative medicine
• Applied: modified islet transplantation analysis
• Stem cell spheroid research
• Cancer research
10.30 Morning Coffee
11.00 Planar spheroid arrays
• The principle of planar spheroid arrays and the
basic idea
• Generating planar spheroid array from
multiplates
• Trouble-shooting and challenges
11.40 Hands-on: trials: make your own array, look at
sections
• Agarose embedding, array retrieval, processing
• Discussion round
12.20 Closing Remarks
12.30 End of Workshop
About the Workshop Leaders:
Michael Raghunath is a physician scientist heading
the Center for Cell Biology & Tissue Engineering at
the Zurich University of Applied Sciences. From 2003-
2016 he was a tenured Associate Professor at the
National University of Singapore (Biomedical Engineering/
Biochemistry/A*STAR Institute for Medical Biology). As council
member of TERMIS-EU, he is experienced in fundamental,
clinical and industrial research with accomplishments in the
fields of in matrix biology (pathobiochemistry of collagens
and elastic microfibrils) and skin biology (wound repair,
cornification disorders). He has pioneered the systematic
use of macromolecular crowding as novel technology
in tissue engineering to build cell-specific and lineage-
directing microenvironments.
Patrick Kugelmeier studied medicine and did
his medical thesis in islet transplantation for the
treatment of Diabetes. The joy of research led to
an MD-PhD program for the early differentiation
of stem cells. Cell culture technologies at that time didn’t
allow for good data reproducibility, because stem cells
were cultured in 2D. Fueled by the clinical need of small,
size-controlled cell clusters to improve islet transplantation
and the insights from the sensitivity of stem cells, he began
to develop what was later to become the Sphericalplate
5D. After the MD-PhD program, he did his clinical training
in visceral and transplant surgery followed by trauma
surgery. Besides the clinical work, the Sphericalplate 5D
was further developed. Finally, it became clear that this
technology opens a new dimension in cell transplantation
and regenerative medicine and Dr. Kugelmeier decided to
quit surgery to fully live this vision within a startup-company,
the Kugelmeiers AG.
Workshop Leaders:
Dr. Patrick Kugelmeier,
Founder, Director of Science, Kugelmeiers
Dr. Michael Raghunath, Professor for Biochemistry,
Protein Technology and Tissue Engineering,
Zurich University of Applied Sciences

5. SMi PHARMACEUTICAL
EVENT PLANNER 2018-19
OCTOBER 2018
Cell & Gene Therapy
10 - 11 October , London, UK
Orphan Drugs & Rare Diseases
17 - 18 October, London, UK
NOVEMBER 2018
USA WEEK
Superbugs & Superdrugs USA
12 - 13 November, New Jersey, USA
Biosimilars North America
14 - 15 November, New Jersey, USA
Lyophilization USA
15 - 16 November, New Jersey, USA
Ophthalmic Drugs
26 - 27 November , London, UK
DECEMBER 2018
Cold Chain Distribution
10 - 11 December, London, UK
JANUARY 2019
Pre-Filled Syringes & Injectable Drug Devices
16 -17 January, London, UK
Pharmaceutical Microbiology
21 - 22 January, London, UK
Social Media in the Pharmaceutical Industry
21 - 22 January, London, UK
FEBRUARY 2019
Parallel Trade
5 - 6 February, London, UK
3D Cell Culture
20 - 21 February, London, UK
RNA Therapeutics
20 - 21 February, London, UK
MARCH 2019
Superbugs & Superdrugs
18th - 19th March 2019, London, UK
Drug Discovery Chemistry
18th - 19th March 2019, London, UK
APRIL 2019
Adaptive Designs
1st - 2nd April 2019, London, UK
Pre-Filled Syringes East Coast
8th - 9th April 2019, Boston, USA
Microbiology East Coast
10th - 11th April 2019, Boston, USA
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and
branding packages, uniquely tailored to complement
your company’s marketing strategy. Prime networking
opportunities exist to entertain, enhance and expand
your client base within the context of an independent
discussion specific to your industry. Should you wish to
join the increasing number of companies benefiting
from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email:
amalick@smi-online.co.uk

6. 3D CELL CULTURE
Conference: 20th - 21st February 2019, Copthorne Tara Hotel, London, UK Workshop: 19th February 2019, Copthorne Tara Hotel, London, UK
4 WAYS TO REGISTER
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
ONLINE at www.3D-cellculture.com
POST your booking form to: Events Team, SMi Group Ltd,
1 Westminster Bridge Road, London, SE1 7XW
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk
Unique Reference Number
Our Reference P-276
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-276 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
SMi Group will apply surcharges to commercial cards
Please tick here □ if the card provided is not a commercial card
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATION
I cannot attend but would like to Purchase access to the following Document Portal/
Paper Copy documentation. Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here
CONFERENCE PRICES GROUP DISCOUNTS AVAILABLE
I would like to attend: (Please tick as appropriate) Fee TOTAL
□ Conference Workshop £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ Workshop only £599.00 + VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject
to distribution rights by speakers. Please note that some presentations may not be
available for download. Access information for the document portal will be sent to
the e-mail address provided during registration. Details are sent within 24 hours post
conference.
□ Book by 31st October to receive £400 off the conference price
□ Book by 30th November to receive £200 off the conference price
□ Book by 14th December to receive £100 off the conference price
EARLY BIRD
DISCOUNT
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
If you would like to continue to receive email updates about our
events, please tick □
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we
have to cancel the event for any reason, then we will make a full refund immediately, but disclaim
any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Privacy policy / Opt Out: For full details on our privacy policy please go to
http://smi-online.co.uk/privacy-legals/privacy-policy. If you no longer wish to receive email
updates you can opt out by going to the following webpage http://www.smi-online.co.uk/opt-out
Terms and Conditions of Booking
DELEGATE DETAILS
VENUE Copthorne Tara Hotel, London, UK
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712